Evidence map›Paper›PMID 42209159›Full record

ArticleZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2026

[Expert recommendations on the management of adverse reactions in pegylated interferon alpha therapy for chronic hepatitis B].

Expert Group on the Management of Adverse Reactions in Pegylated Interferon Alpha Therapy for Chronic Hepatitis B

Abstract readEnglish Abstract
In one paragraph

Article in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Expert Group on the Management of Adverse Reactions in Pegylated Interferon Alpha Therapy for Chronic Hepatitis B

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To provide a usage reference for clinicians with the increasing use of pegylated interferon alpha (PEG-IFN-ɑ) in treating chronic hepatitis B (CHB), the expert panel retrospectively summarized previous clinical experience and formulated expert recommendations based on the latest research findings and evidence-based medical data of this field, focusing on pre-treatment assessment to better assist clinicians in managing adverse reactions, help patients complete treatment courses, and maximize patient benefits.

Indexed as

Antiviral AgentsHepatitis B, ChronicInterferon-alphaPolyethylene GlycolsHumansInterferon alpha-2Recombinant ProteinsAntiviral AgentsInterferon-alphaInterferon alpha-2peginterferon alfa-2aPolyethylene GlycolsRecombinant Proteins

Identifiers

PMID42209159
PMCPMC13223770

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.